| Wyeth damages motion granted by court | Posted on 10/07/2008 in Pharmaceutical Company Product News Wyeth has announced that its motion for judgement on a matter of law regarding punitive damages in a case relating to its oestrogen treatments has been granted by a district court.
The US District Court in the Eastern District of Arkansas has vacated the punitive damages award of $19.36 million (9.78 million pounds) awarded by the jury in the case of Donna Scroggin v Wyeth last year.
Wyeth said this decision also clears the way for an appeal of the compensatory damages award of $2.75 million.
In the original case, the plaintiff claimed her treatment with Premarin (conjugated oestrogens tablets USP) and Pempro (conjugated estrogens/medroxyprogesterone acetate tablets) resulted in her development of breast cancer.
Lyn P Pruitt, an attorney representing Wyeth with Mitchell, Williams, Selig, Gates & Woodyard, said: "We always believed there was no basis in fact or law for either award in this case."
She added that the company is pleased with the court's decision to vacate punitive damages and is looking forward to presenting its appeal against the compensatory damages to the court of appeals.
In May 2007, Wyeth announced that it had won the case of Merle and Steven Simon v Wyeth in Philadelphia relating to Pempro and Premarin.Other news stories from 10/07/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
